Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
RGX-202 by RegenxBio for Duchenne Muscular Dystrophy: Likelihood of Approval
RGX-202 is under clinical development by RegenxBio and currently in Phase II for Duchenne Muscular Dystrophy. According to GlobalData, Phase...
Data Insights
Risk adjusted net present value: What is the current valuation of RegenxBio's RGX-202?
RGX-202 is a gene therapy commercialized by RegenxBio, with a leading Phase II program in Duchenne Muscular Dystrophy. According to...